{"id":8130,"date":"2024-04-16T09:00:33","date_gmt":"2024-04-16T00:00:33","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/eng\/?page_id=8130"},"modified":"2024-04-12T11:29:22","modified_gmt":"2024-04-12T02:29:22","slug":"wada2024-4-9","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/eng\/activities\/results\/2024year\/wada2024-4-9","title":{"rendered":"Kota Iwahori, Hisashi Wada \u226aClinical Research in Tumor Immunology\u226b Mari Tone, Atsushi Kumanogoh \u226aRespiratory Medicine and Clinical Immunology\u226b <span>Antibiotics reveal a new way to fight cancer<\/span>"},"content":{"rendered":"<ul class=\"linkBar clearfix\">\n<li><a href=\"https:\/\/www.med.osaka-u.ac.jp\/activities\/results\/2024year\/wada2024-4-9\">Text in Japanese<\/a><\/li>\n<\/ul>\n<p><span class=\"lineFrame\">Journal for ImmunoTherapy of Cancer<\/span><\/p>\n<p><em>Researchers from Osaka University use tetracycline antibiotics to identify targets for novel cancer immunotherapies<\/em><\/p>\n<p class=\"figure\"><a href=\"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2024\/04\/iwahori_efig.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-8210 size-medium\" src=\"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2024\/04\/iwahori_efig-400x274.jpg?_t=1712196741\" alt=\"\" width=\"400\" height=\"274\" srcset=\"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2024\/04\/iwahori_efig-400x274.jpg 400w, https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2024\/04\/iwahori_efig-768x525.jpg 768w, https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2024\/04\/iwahori_efig.jpg 886w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/><\/a><br \/>Figure 1. Tetracyclines enhanced T-cell cytotoxicity to tumor cells<\/p>\n<div class=\"TextBlock\">\n<p>Cancer cells grow and spread by hiding from the body\u2019s immune system. Immunotherapy allows the immune system to find and attack hidden cancer cells, helping cancer patients live longer lives. However, many patients get little or no benefit from these revolutionary treatments.<\/p>\n<p>Immune checkpoint inhibitors are the most used immunotherapies. They work by recognizing and blocking proteins that cancer cells use to hide from the immune system. However, cancer cells that don\u2019t have these proteins use different ways to hide. Since patients with these cancers don\u2019t respond to immune checkpoint inhibitors, researchers are keen to develop new immunotherapies with different targets.<\/p>\n<p>In a study published in the <em>Journal for ImmunoTherapy of Cancer<\/em>, researchers from Osaka University have discovered that tetracycline antibiotics help the immune system to find cancer cells in a way that is different from current immunotherapies. These antibiotics stimulate immune cells, known as T lymphocytes, to attack and destroy cancer cells.<\/p>\n<p>\u201cWe investigated the tetracycline antibiotic minocycline in blood and tumor tissue from lung cancer patients,\u201d says lead author Mari Tone. \u201cWe found that minocycline enhanced the antitumor activity of T lymphocytes by targeting galactin-1, which is an immunosuppressive protein produced by cancer cells.\u201d<\/p>\n<p>The team found that galactin-1 helps cancer cells hide from the immune system by preventing cytotoxic T lymphocytes from reaching the tumor. After treatment with tetracycline, galactin-1 was no longer able to stop the T lymphocytes from attacking the tumor. Blocking galactin-1 might just be the key to new cancer treatments.<\/p>\n<p>\u201cThese antibiotics have a different mechanism of action from immune checkpoint inhibitors and other immunotherapies used to treat cancer,\u201d says corresponding author Kota Iwahori. \u201cWe hope this research will lead to the development of new drugs that target different immune pathways and can benefit people with cancer, particularly those who don\u2019t benefit from current immunotherapies.\u201d<\/p>\n<p>Tetracycline antibiotics have been used to treat patients with infectious diseases for many years worldwide. Now, these old drugs may point the way to new immunotherapies for cancer patients who currently have few treatment options.<\/p>\n<\/div>\n<p>###<\/p>\n<p>The article, \u201cTetracyclines enhance anti-tumor T cell immunity via the Zap70 signaling pathway,\u201d was published in <em>Journal for ImmunoTherapy of Cancer <\/em>at DOI: <a href=\"http:\/\/dx.doi.org\/10.1136\/jitc-2023-008334\">http:\/\/dx.doi.org\/10.1136\/jitc-2023-008334<\/a>.<\/p>\n<p><strong>Summary:<\/strong> Researchers from Osaka University found that tetracycline antibiotics stimulate T lymphocytes in the body\u2019s immune system to attack and destroy cancer cells. The antibiotics work by blocking the action of galactin-1, a protein made by cancer cells that suppresses the immune system. Identification of this new target may lead to the development of novel cancer immunotherapies.<\/p>\n<p><strong>Tweet <\/strong>: Research out of @osaka_univ_e reveals that #galactin-1 could be a target for novel #cancer #immunotherapies<\/p>\n<p><strong>Primary Keyword<\/strong>: Health and medicine<br \/><strong>Additional Keywords<\/strong>:\u00a0Cancer immunotherapy, cancer research, lung cancer, immune system, immune cells, T cell responses, drug targets<\/p>\n<p><strong>Method of Research<\/strong>: Experimental study<\/p>\n<p><strong>Subject of Research<\/strong>: Human tissue samples<\/p>\n<div class=\"TextBlock\">\n<p>Title: \u201cTetracyclines enhance anti-tumor T cell immunity via the Zap70 signaling pathway\u201d<\/p>\n<\/div>\n<p>Journal: <em>Journal for ImmunoTherapy of Cancer<\/em><em><br \/><\/em>Authors: Mari Tone, Kota Iwahori, Michinari Hirata, Azumi Ueyama, Akiyoshi Tani, Jun-Ichi Haruta, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh, Hisashi Wada.<br \/>DOI: <a href=\"http:\/\/dx.doi.org\/10.1136\/jitc-2023-008334\">10.1136\/jitc-2023-008334<\/a><\/p>\n<p>Japan Society for the Promotion of Science (JSPS)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Text in Japanese Journal for ImmunoTherapy of Cancer Researchers from Osaka University use tetracycline antibi [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8210,"parent":8108,"menu_order":38,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/8130"}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/comments?post=8130"}],"version-history":[{"count":16,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/8130\/revisions"}],"predecessor-version":[{"id":8231,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/8130\/revisions\/8231"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/8108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/media\/8210"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/media?parent=8130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}